NIAID Pushes for Vaccine Development

The National Institute of Allergy and Infectious Diseases (NIAID) is responding full force to President Bill Clinton's call to increase vaccine development efforts against globally important diseases such as AIDS, tuberculosis (TB), and malaria. "Vaccines are a major public health tool, so it makes sense that more public dollars should be spent on this research," says Margaret Johnston, assistant director for AIDS vaccines at NIAID. NIAID has launched four novel public-private partnerships, which $70 million in funding will support over the next five years. The research organizations that have received an award include Advanced BioScience Laboratories Inc., Kensington, Md.; Chiron Corp., Emeryville, Calif.; University of New South Wales, Australia; and Wyeth Lederle Vaccines and Nutrition, Pearl River, N.Y. The four contracts propose using different DNA-based HIV vaccine approaches. A DNA-based vaccine uses genetic information to make specific HIV proteins to induce an immune...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?